This article is more than 5 years old. Information may no longer be current.
Botox treatment improved lower urinary tract symptoms in patients with bladder cancer
Click Here to Manage Email Alerts
Baseline PSA and prostate volume may predict treatment success when considering botulinum toxin-A therapy for the treatment of lower urinary tract symptoms, according to new findings.
For the multicenter, phase 2 study (MIST2 Trial), researchers assessed whether examining prostate volume and PSA score was influenced by botox injection (BoNT-A or Botox) for the treatment of lower urinary tract symptoms in men aged 50 years or older.
Men were randomly assigned 100 units (n=63) or 300 units (n=53) of botox injection. Follow-up was at 4, 8 and 12 weeks and again at 1 year. Researchers assessed prostate volume, serum PSA, American Urological Association Symptom Score, BPH II, Qmax and post-void residual volume at baseline, week 12 and 1 year.
A 37.4% reduction was observed at 12 weeks for American Urological Association symptom scores (11.1) and Qmax score (12.4; 27.7% increase from baseline) — no changes were observed in total prostate volume, transition zone volume or PSA. At 1 year, researchers observed a significant difference in American Urological Association symptom scores (12.1; 35.6% reduction from baseline), Qmax (12; 27.6% increase from baseline) — with change in volume or PSA.
For more information:
- McVary K. #1780.